Imaging study of a new tracer for cancer detection
Part of Brain & nervous system, Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new imaging tracer called [89Zr]DFO-YS5 that may help detect certain cancers on a PET-CT scan. The goal is to see if this tracer is safe and works well for finding tumors, which could one day help doctors plan better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a malignant peripheral nerve sheath tumor, bladder cancer, or another solid tumor.
- You must have at least one tumor that is 1 centimeter or larger on a CT, MRI, or PET scan. For bladder cancer that hasn't been removed yet, smaller tumors are okay if confirmed by cystoscopy.
- You must be able to undergo a PET-CT scan (no severe claustrophobia or metal implants).
- You must be 18 years old or older.
- You must be reasonably active and able to do daily activities (ECOG score of 2 or less).
- Your liver and kidney function must be within acceptable ranges, and if you are of childbearing potential, you must have a negative pregnancy test before the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.
This study tests a new type of imaging agent (called a tracer) that helps PET scans see tumors more clearly. It may help doctors find and monitor cancer better.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This study tests a new PET scan tracer that aims to highlight cancer cells more clearly. If you join, you'll receive one injection of the tracer and then have a PET/CT scan to help your doctor see whether you have cancer or where it is.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.